We recently started to work with Consilium and immediately they became a vital part of iSonea's team. The Consilium analystís understanding of investor markets has been invaluable across a range of issues and opportunities. Consilium's understanding of our business and industry also contributed to it becoming a trusted associate that was integral in helping design our strategic direction. Two of Consilium's greatest assets are its knowledge of Wall Street and its ability to focus companies on the issues most relevant.

Michael J Thomas - CEO, iSonea Ltd

Consiliumís expertise in health care and its ability to communicate our corporate achievements and potential in a useful format for the investment community has been valuable and much appreciated. From day one, they were able to clarify our business strategies without over simplifying the facts. Additionally, they have numerous buy side relationships to help cultivate our success with Wall Street.

Bryan Dulhunty - Managing Director & CEO, Viralytics Ltd

Consilium Global Research recently wrote a comprehensive research report of Neogenix Oncology and we were extremely pleased with the final result. The report provided an in-depth yet balanced examination of our company, presenting what is a complicated story in a manner that is more lucid and informative to our investors. Consilium is a group of highly experienced Wall St. analysts and that experience was self evident in our ongoing discussions with them and in the preparation of their report.

Peter Gordon, CFO, Neogenix Oncology